Safety of nivolumab in metastatic renal cell carcinoma patients: A real-life experience in a Spanish urology setting
Volume: 43, Issue: 7, Pages: 364 - 370
Published: Sep 1, 2019
Abstract
Nivolumab is an immunotherapy agent that has been an approved treatment for previously treated patients with advanced renal cell carcinoma (RCC). Experience in real-life settings, especially regarding immune-related adverse events, is scarce. We present our experience with reference to the safety of nivolumab in patients with metastatic RCC (mRCC) treated in 9 hospitals in Spain. Retrospective, multicenter study of patients with mRCC treated...
Paper Details
Title
Safety of nivolumab in metastatic renal cell carcinoma patients: A real-life experience in a Spanish urology setting
Published Date
Sep 1, 2019
Volume
43
Issue
7
Pages
364 - 370
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History